抗IL-5/5Ra治疗在嗜酸性粒细胞性哮喘中的累积激素节约效应
这项基于荷兰重度哮喘登记(RAPSODI)的真实世界观察性研究纳入389例重度嗜酸性粒细胞性哮喘成人,比较启动抗IL-5/5Ra治疗前后2年的累积口服激素(OCS)暴露。结果显示中位累积OCS暴露从2.715克降至1.050克(p<0.001),52%的患者在2年内停用OCS,且既往OCS暴露较低、较短者更可能完全停用。
要点
- 抗IL-5/5Ra治疗可显著降低2年累积口服激素暴露。
- 52%的重度嗜酸性粒细胞性哮喘患者可在2年内停用口服激素。
- 既往口服激素暴露较低、较短者更可能完全停用口服激素。
核心结论
- 抗IL-5/5Ra治疗可显著降低重度嗜酸性粒细胞性哮喘患者2年累积口服激素暴露。
- 既往口服激素暴露较低且较短的患者更可能在2年内完全停用口服激素。
- 由于启动抗IL-5/5Ra前累积激素暴露逐步增加,早期干预可能带来更好的长期预后。
研究设计与样本
- 真实世界全国性观察性登记研究,基于荷兰重度哮喘登记(RAPSODI)。
- 纳入389例重度嗜酸性粒细胞性哮喘成人,评估启动抗IL-5/5Ra前后各2年所有配发的口服激素。
- 采用Wilcoxon符号秩检验和多变量回归分析。
主要发现
- 启动抗IL-5/5Ra前后2年中位累积口服激素暴露从2.715(1.150-5.539)克降至1.050(0.300-3.640)克(p<0.001)。
- 52%的患者在启动抗IL-5/5Ra治疗后2年内能够停用口服激素。
- 停用口服激素独立预测因素为既往口服激素暴露较低和较短。
临床怎么用
- 对重度嗜酸性粒细胞性哮喘患者,抗IL-5/5Ra治疗可显著减少累积口服激素暴露。
- 既往口服激素暴露较低、较短者更可能完全停用口服激素,提示早期启动抗IL-5/5Ra可能改善长期预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-interleukin (IL)-5/IL-5 receptor α (IL-5Ra) therapy has been shown to reduce maintenance oral corticosteroid (OCS) dose in severe eosinophilic asthma. However, the effect on cumulative OCS exposure is currently unknown. Neither is it known how prior OCS exposure affects response to anti-IL-5/5Ra treatment. We aimed primarily to compare the cumulative OCS exposure over a 2-year period before and after anti-IL-5/5Ra initiation, and secondarily to investigate whether duration and cumulative OCS exposure prior to anti-IL-5/5Ra influence the ability to discontinue OCS within 2 years of anti-IL-5/5Ra therapy. METHODS: This real-world nationwide observational registry-based study evaluated all dispensed OCS from 389 adults with severe eosinophilic asthma included in the Dutch Severe Asthma Registry (RAPSODI) 2 years before and 2 years after initiating anti-IL-5/5Ra. The Wilcoxon signed-rank test and multivariable regression analyses were used. RESULTS: Median (interquartile range) cumulative OCS exposure in the 2 years before and after anti-IL-5/5Ra initiation decreased from 2.715 (1.150-5.539) to 1.050 (0.300-3.640) g (p<0.001). 52% of patients were able to discontinue OCS within 2 years after anti-IL-5/5Ra therapy, which was independently predicted by lower and shorter prior OCS exposure. CONCLUSIONS: This real-world study showed that anti-IL-5/5Ra therapy leads to a significant reduction in cumulative OCS exposure over a 2-year period. Patients with lower and shorter OCS exposure were more likely to completely eliminate OCS. Since cumulative exposure increased progressively prior to anti-IL-5/5Ra initiation, our data suggest that early intervention leads to a better long-term prognosis in patients with severe eosinophilic asthma.
引用
- Kroes JA, Zielhuis SWJ, De Jong K, et al. Cumulative corticosteroid-sparing effect of anti-interleukin-5/5Ra in eosinophilic asthma. Eur Respir J. 2022. PMID: 35595317. doi:10.1183/13993003.02983-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。